TAK 733 clinical trials
Also written REC-4881.
How each study uses TAK 733 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TAK 733 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2009 (1)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Millennium Pharmaceuticals, Inc. (2) · Recursion Pharmaceuticals Inc. (2)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test TAK 733.
- Jun 2027Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)Phase 1/2 · Recursion Pharmaceuticals Inc.
Studies
Open first, then newest update. How each study uses TAK 733 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)RecruitingPhase 1/2Recursion Pharmaceuticals Inc.NCT05552755Written as REC-4881
- A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC MutationTerminatedPhase 2Recursion Pharmaceuticals Inc.NCT06005974Written as REC-4881
- Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic MalignanciesWithdrawnPhase 1Millennium Pharmaceuticals, Inc.NCT01613261Written as TAK-733 and alisertib
- Study of TAK-733 in Adult Patients With Advanced Nonhematologic MalignanciesCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT00948467Written as TAK-733
Codes
What other systems call TAK 733 · ClinicalTrials.gg INT005841
- UNII (FDA) 5J61HSP0QJTAK-733Confirmed FDA, Wikidata
- Wikidata Q27262384tak-733Confirmed FDA, Wikidata
- DrugBank DB12241One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5J61HSP0QJ | TAK-733 | Confirmed FDA, Wikidata |
| Wikidata | Q27262384 | tak-733 | Confirmed FDA, Wikidata |
| DrugBank | DB12241 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.